Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 ·Status: COMPLETED

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

NCT06492447 ·Status: NOT_YET_RECRUITING

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

NCT05839288 ·Status: COMPLETED

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

NCT06722612 ·Status: RECRUITING

HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

NCT05834686 ·Status: UNKNOWN

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

NCT06711055 ·Status: RECRUITING

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

NCT06254690 ·Status: RECRUITING ·Phase: PHASE2

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

NCT06711068 ·Status: RECRUITING

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

NCT05165225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

NCT06693024 ·Status: RECRUITING

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

NCT04034589 ·Status: UNKNOWN ·Phase: PHASE2

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

NCT06548919 ·Status: RECRUITING

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

NCT06561022 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

NCT05255523 ·Status: UNKNOWN ·Phase: PHASE2

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

NCT03366428 ·Status: COMPLETED ·Phase: PHASE1

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334 ·Status: COMPLETED

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

NCT06495541 ·Status: NOT_YET_RECRUITING ·Phase: NA

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

NCT06641544 ·Status: RECRUITING ·Phase: PHASE4